Dupilumab in the treatment of asthma.

Dupilumab is a fully human monoclonal IgG4 antibody that blocks IL-4 and IL-13 signaling. Its efficacy has been assessed across a range of atopic diseases, due to its ability to inhibit T helper cell 2 (Th2) mediated inflammation. It has already been approved in the USA and Europe for the treatment of atopic dermatitis. Recently, it also gained approval in the USA as add-on treatment for moderate-to-severe asthma in adolescents and adults. Phase II and III randomized controlled trials have demonstrated improvements in asthma exacerbation rates, FEV1, oral glucocorticoid use and a range of patient-reported outcomes, with a favorable safety profile. This article will review the available clinical trial data relating to the efficacy and safety of dupilumab in the management of asthma and related atopic respiratory conditions.